FDA approves Voxzogo for children, first drug to improve growth in most common form of dwarfism

In November 2021, the U.S. Food and Drug Administration (FDA) approved Voxzogo (vosoritide) injection to improve growth in children 5 years of age and older with achondroplasia and open epiphyses (growth plates), meaning these children still have the potential to grow. Achondroplasia is the most common form of dwarfism.